These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11857004)

  • 1. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide.
    Siderov J; Prasad P; De Boer R; Desai J
    Br J Cancer; 2002 Jan; 86(1):12-3. PubMed ID: 11857004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide.
    Bernstein BJ; Troner MB
    Pharmacotherapy; 1999 Aug; 19(8):989-91. PubMed ID: 10453971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypersensitivity reactions to etoposide phosphate.
    Sambasivan K; Mahmoud S; Kokache A; Seckl M; Savage P
    J Oncol Pharm Pract; 2014 Apr; 20(2):158-60. PubMed ID: 23740378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity.
    Collier K; Schink C; Young AM; How K; Seckl M; Savage P
    J Oncol Pharm Pract; 2008 Mar; 14(1):51-5. PubMed ID: 18337441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity.
    Brooks JP; Azmy V; Thompson A; Luon D; Prozora SD; Price C; Hsu FI
    J Oncol Pharm Pract; 2020 Jan; 26(1):228-231. PubMed ID: 30885040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Treatment with Etoposide Base after an Acute Hypersensitivity Reaction to Etoposide Phosphate.
    Leguay Z; Bourneau-Martin D; Pellier I; Le Louet H; Drablier G; Lagarce L; Lainé-Cessac P
    Pediatr Blood Cancer; 2016 Mar; 63(3):571. PubMed ID: 26468691
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer.
    Soni N; Meropol NJ; Pendyala L; Noel D; Schacter LP; Gunton KE; Creaven PJ
    J Clin Oncol; 1997 Feb; 15(2):766-72. PubMed ID: 9053503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immediate severe hypersensitivity reaction to etoposide phosphate: Case report and review of the literature.
    Pringle NR; Gilbar PJ; Grewal GD
    J Oncol Pharm Pract; 2022 Jun; 28(4):1019-1023. PubMed ID: 35037804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early studies of etoposide phosphate, a water-soluble prodrug.
    Budman DR
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):8-14. PubMed ID: 8996570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of etoposide phosphate.
    Brooks DJ; Srinivas NR; Alberts DS; Thomas T; Igwemzie LM; McKinney LM; Randolph J; Schacter L; Kaul S; Barbhaiya RH
    Anticancer Drugs; 1995 Oct; 6(5):637-44. PubMed ID: 8845473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of etoposide phosphate plus paclitaxel.
    Brooks DJ; Alberts DS
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):30-3. PubMed ID: 8996573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients.
    Kaul S; Srinivas NR; Mummaneni V; Igwemezie LN; Barbhaiya RH
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):23-9. PubMed ID: 8996572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients.
    Kaul S; Srinivas NR; Igwemezie LN; Barbhaiya RH
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):15-22. PubMed ID: 8996571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide phosphate or etoposide with cisplatin in the treatment of small cell lung cancer: randomized phase II trial.
    Greco FA; Hainsworth JD
    Lung Cancer; 1995 Jun; 12 Suppl 3():S85-95. PubMed ID: 7551961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoposide phosphate, the water soluble prodrug of etoposide.
    Witterland AH; Koks CH; Beijnen JH
    Pharm World Sci; 1996 Oct; 18(5):163-70. PubMed ID: 8933576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease.
    Hudson MM; Weinstein HJ; Donaldson SS; Greenwald C; Kun L; Tarbell NJ; Humphrey WA; Rupp C; Marina NM; Wilimas J
    J Clin Oncol; 1993 Jun; 11(6):1080-4. PubMed ID: 8501494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of high dose etoposide phosphatase with filgrastim (G-CSF) in the treatment of advanced refractory malignancies.
    Hainsworth JD; Utley SM; Greco FA
    Invest New Drugs; 1997; 15(4):325-9. PubMed ID: 9547675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
    Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K
    J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
    Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
    Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.